With the development of osimertinib as the new standard of care for metastatic EGFR-mutated NSCLC, the ADAURA study compared osimertinib to placebo in resected stage IB–IIIA EGFR-positive NSCLC [9]. Here, EGFR is linked to non-small cell lung carcinoma.